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[ ]Sweat  testing practices in Swiss hospitals 
J. Barben 1, C. Casaulta 2, M-C. Desax 2, M.H. Schoeni 2. 1Pulmonology, Children ~' 
HosTital, St. Gallen; 2Departments of Pediatrics, University of Berne, Switzerland 
Aims: To determine whether the current practice of sweat esting in Swiss hospitals 
is consistent with the current guidelines. 
Methods: A questionnaire was mailed to all tertiary children's hospitals ( n 8) 
and regional paediatric sections of adult hospitals in 28) as well as to all adult 
pulmonology centres in 8) in Switzerland which care for patients with cystic 
fibrosis (CF). The results were compared with the guidelines of the American 
National Committee for Clinical Laboratory Standards (NCCLS). 
Results: The response rate to the questionnaire was 84%. 25 out of 29 children's 
hospitals perform sweat ests but none of the adult pulmonology centres. All centres 
carried out in total 1500 sweat tests (range: 5 200, median 40) by pilocarpine 
iontophoresis per year. 72% (18 out of 25) are using the Macroduct system 
for collecting sweat. 32% are using the new Nanoduct as screening method. 
Chloride was investigated by only 60% of all centres; of them, only 60% used 
the recommended chloride CF-reference value of >60retool/1. Osmolality was 
measured in 36%, sodium in 44% and conductivity in 52% of the hospitals. Sweat 
was collected for maximal 30 120 (median 55) minutes; only 3 centers used the 
recommended maximal 30 minutes ample time by the NCCLS. 
Conclusions: Sweat esting practice in Swiss hospitals is inconsistent and does not 
follow the NCCLS-guidelines for sweat collection, analyzing method and reference 
values. Only 60% are using the chloride reference, the actual still only accepted 
diagnostic measurement by the NCCLS. 
12. Screening 
1~ Rapid and reliable genotyping of polymorphic loci influencing 
correct splicing of CFTR pre-mRNA using mass spectrometry 
A. Schaller 1, T. Yon K~inel 1, B. Gehr 2, J. Sanz 1 , S. Gallati 1 . 1Division of Human 
Genetics', University of Bern, 3010 Bern; 2Institute of Biochemistry and Molecular 
Biology, University of Bern, 3012 Bern, Switzerland 
Aims: We describe a fast and unambiguous method for haplotyping the (TG)mTn 
repeat in IVS8 and determining three other SNPs in exons 10, 14a and 24 in 
the CFTR gene affecting correct splicing of the CFTR pre-mRNA using primer 
extension and mass spectrometry. 
Methods: The diagnostic products are generated by primer extension (PEX) 
reactions, which require a single detection primer complementary to a region 
downstream of a target strand's variable site. On addition of a polymerase, an 
appropriate mixture of dNTP's and ddNTP's, the primer is extended through the 
mutation region until the first ddNTP is incorporated and the mass of the extension 
products determines the composition of the variable site. 
Results: Analysis of patient DNA assigned the correct and unambiguous haplotype 
for the (TG)mTn repeat in intron 8 of the CFTR gene. Additional crucial SNPs 
influencing correct splicing in exon 10, 14 and 24 can easily be detected by biplexing 
the assay. 
Conclusions: Different PEX reactions with subsequent mass spectrometry generate 
sufficient data, to enable unambiguous and easy haplotyping of the (TG)mTn repeat 
in the CFTR gene. The method can be easily extended to the inclusion of additional 
SNPs of interest by biplexing some of the PEX reactions to genotype allelic variants 
important for correct splicing of the CFTR pre-mRNA. All experimental steps 
required for PEX are amenable to the high degree of automation desirable for a 
high-throughput diagnostic setting. 
A.S. and %VK. contributed equally to this work 
[ ] N a s a l  potential difference measurements in Turkish CF patients 
G. Cinel 1 , M. Sevgili 2, D. Balkan@ 2, I. Karabulut 2, D. Dogru 1 , E. Yalcin 1 , 
N. Cobanoglu 1 , S. Pekcan 1, U. Ozcelik 1 , M. Kaplan 1, N. Kiper 1 . 1Pediatric 
Pulmonology Unit, 2physiology Department, Hacettepe University Medical School, 
Ankara, Turkey 
Introduction: Because of the defective cystic fibrosis transmembrane regulator 
protein (CFTR), abnormal airway epithelial sodium and chloride transport is the 
characteristic of cystic fibrosis (CF). In vivo measurement of nasal potential 
difference (NPD) can define this ion transport abnormalities which are characteristic 
for CF; so it has been advocated as a diagnostic tool for classical and atypical CF 
patients. 
Aim: To assess the difference of NPD measurements between CF and non-CF 
subjects. 
Method: NPD measurement was applied to 23 CF and 37 non-CF subjects. Basal 
NPD, maximum NPD with ringer lactate solution (max NPD), response to amiloride 
((Samil), chloride free solution ((50CL) and isoproterenol ((Siso) were measured. 
Results: Mean values of basal NPD was 37.27 and 24.34; max NPD was 
49.37 and 26.72; NPD with amiloride was 28.61 and 18.67; NPD with 
chloride free solution (0CL) was 29.65 and 27.68; NPD with isoproterenol was 
29.44 and 34.63 millivolts (mV) in CF and non-CF groups respectively. Using 
T-Test, we found significant difference between CF and non-CF subjects on basal 
NPD, max NPD and measurement wi h amiloride; but measurement wi h 0CL and 
isoproterenol were not different. Also, mean values of(Samil was 20.75 and 8.04; 
60CL was 1.03 and 9.00; 6iso was 0.2 and 6.9; 6iso+0CL was 0.83 and 15.96 
mV in CF and non-CF groups respectively and there was a significant difference 
between two groups. 
Conclusion: NPD measurement is a reliable diagnostic tool for CF which shows 
CFTR dysfunction easily in vivo. 
1• Detection of CFTR mutations using a 4-MATTM microarray 
technology 
C. Van Loon, R Van West, A. Verhelst, G. Verpooten, R. Rossau. Innogenetics NV, 
Gent, Belgium 
In order to attain higher overall detection rates of CFTR gene mutations, there is 
a tendency in several countries to move to screening. This implies more typing 
of multi-ethnic mutations. Most typing technologies are limited in the number of 
parameters that can be tested. In order to overcome this problem, we are using an 
innovative microarray technology platform, the 4-MATTM system that can contain 
up to 400 probes, for the development of a CFTR genotyping assay. 
The 4-MATTM system is an automated multiparameter sting approach that applies 
in-licensed microarray technology for diagnostic assays. The technology platform 
is based on the binding of oligonucleotide probes or proteins, that are immobilized 
on a porous membrane, with labeled test molecules uch as DNA amplicons (eg, 
for genetic testing) or proteins (eg, for antibody detection). The membrane is
incorporated in the wells of a disposable unit known as a chip; each chip contains 
four wells, with each well holding a microarray. When binding occurs between 
the test sample and a probe or protein, the resulting fluorescence is recorded. All 
incubation and reading steps are fully automated and are performed by using the 
thermostatically controlled 4-MATTM Instrument. 
The supporting 4-MATTM Master software provides real-time reading, interprets 
the results and generates a report providing the final typing or reactivity result. 
